Alheraki, Samee Zane Masauding

Purpose: Neuroendocrine neoplasms (NENs) are increasingly recognized to have a hereditary predilection, yet the prevalence and clinical relevance of pathogenic germline variants (PGVs) in unselected patients with NEN remain poorly defined. This prospective, multicenter study aimed to evaluate the prevalence and clinical utility of PGVs through universal multigene panel testing in a diverse cohort of patients with NENs. Patients and Methods: Between 2018 and 2024, we enrolled unselected patients with NENs from 3 Mayo Clinic Cancer Centers. Germline genetic testing was performed using a next-generation sequencing panel of up to 84 cancer predisposition genes. Patients were not selected based on age, disease stage, ethnicity, or family history. Variants were classified as PGVs, variants of uncertain significance (VUS), or negative. Clinical and demographic data were analyzed descriptively. Results: Among 88 patients, PGVs were identified in 15.9% (n=14), most frequently in high- or moderate-penetrance genes including MEN1 , CHEK2 , MITF , and MUTYH . PGVs were most commonly found in pancreatic NENs [n=12/55 (21.8%)], followed by small bowel NENs [n=2/20 (10%)], with no PGVs detected in lung NENs. Mismatch repair (MMR) gene alterations were identified in 5.7% of patients, including 1 MLH1 PGV and 4 MSH2/MSH6 VUS, 2 of which demonstrated MMR deficiency by protein testing. VUS were reported in 34.1% of patients. Notably, 35.7% of PGV-positive patients did not meet current NCCN or ACMG testing criteria, and 53.9% had PGVs in genes outside of cancer-specific guideline recommendations. Conclusions: Universal germline testing in unselected patients with NEN identified clinically relevant PGVs in over 15% of cases. These findings support broader genetic testing approaches to guide treatment, enhance familial risk assessment, and inform cascade testing—regardless of traditional clinical selection criteria.

Abstract Disclosure: S.M. Alheraki: None. M.H. Horani: None. F.Z. Alharraki: None. Cushing syndrome is one of the endocrine diseases that is mainly due to the high levels of cortisol. An overproduction of adrenocorticotropic hormone (ACTH) by a pituitary adenoma or an ectopic, paraneoplastic foci (small cell lung cancer) is the primary cause of secondary hypercortisolism. While small cell lung cancer and carcinoids cause the majority of ectopic ACTH syndromes, in this article, we describe a case of Cushing syndrome secondary to lung adenocarcinoma. It is highly likely that patients with malignancies are suffering from ectopic ACTH syndrome if they exhibit clinical signs such as weakness, hypertension, or lab values indicating hyperglycemia, hypokalemia, or metabolic alkalosis. Presentation: Friday, June 16, 2023